Clinical trial · Observational
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment
Epidermal Growth Factor Receptor (EGFR) Mutation Detection From Advanced Non-small Cell Lung Cancer Tissue and Plasma in Tyrosine Kinase Inhibitor (TKI) Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study has been designed in order to detect EGFR mutation abundance of tissue and concentration of plasma from Advanced Non-small Cell Lung Cancer during treatment with Tyrosine Kinase Inhibitor (TKI) .Through this experiment the investigators aim to evaluate the feasibility of plasma EGFR detection and evaluate the correlation of EGFR mutations and prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients advanced NSCLC EGFR mutated
- description
- This is an observational study, there is no intervention.
Primary outcomes (2)
- measure
- EGFR Mutation Detection of FFPE and plasma samples
- timeFrame
- baseline
- description
- To evaluate the feasibility of plasma EGFR detection from non-small cell lung cancer patients harboring EGFR activating mutation who are being treated with EGFR TKIs and evaluate the correlation of EGFR mutations and prognosis.
- measure
- EGFR Mutation Detection of plasma samples for the following-up patients who take TKI.
- timeFrame
- From start of treatment to time of progression or death, whichever occurs first, assessed up to 3 years
- description
- In order to monitor the change of plasma EGFR mutation copy number.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age older than 18 years and under 75 years * Histologically and cytologically proven non-small Cell Lung Cancer * Clinical stages Ⅲ \~ Ⅳ * Not receive any anti-tumor treatment * Eastern cooperative oncology group performance status (ECOG PS) =1\~2 * Estimated survival time more than 3 months * EGFR-TKI treatment for first-line or second-line * Voluntary to participate in this clinical trial and sign the consent form Exclusion Criteria: * Patients have received EGFR-TKI therapy before the study * With other malignancy history in the recent 5 years before the study * Pregnancy or breast feeding phase * Inadequate samples for testing * Follow-up compliance is poor
References
Publications (0)
Data not yet available